Vgenomics, a precision health company, and Meril Genomics, a diagnostics and molecular biology provider, have announced a partnership aimed at providing complementary advanced genomic diagnostics to hospitals and research centers throughout India. This collaboration combines Vgenomics’ expertise in bioinformatics, AI-driven research, and translational genomics with Meril Genomics’ capabilities in diagnostics and molecular biology.
The partnership aims to enhance precision medicine accessibility. Initiatives under this partnership include Non-Invasive Prenatal Testing (NIPT), which addresses the growing risk of chromosomal abnormalities such as Down syndrome, especially among expectant mothers with advanced maternal age. NIPT will facilitate early detection, contributing to safer pregnancies and healthier newborn outcomes across India.
In addition, the collaboration introduces targeted Next-Generation Sequencing (tNGS) for Tuberculosis (TB), significantly impacting India’s healthcare landscape, where roughly 26 per cent of Global TB cases occur annually. By enabling rapid and precise detection, tNGS aims to facilitate timely treatment and effective management of the disease.
Furthermore, the initiative includes Whole Exome Sequencing (WES) for diagnosing rare diseases, addressing the needs of approximately 70 million affected individuals in India. Integrating WES with advanced AI analytics will significantly accelerate diagnostic timelines, enhance personalised treatment approaches, and reduce the prolonged diagnostic journey often faced by rare disease patients.